Pharmafile Logo

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas

Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments.

- PMLiVE

At Fishawack Health (FH), we are committed to investing in the field of dermatology. In November 2021, we welcomed FIDE, an independent network of expert partners in dermatology, to inform industry specialists as to the potential impact of the latest data and how it may affect their strategic decision making. FIDE joins other Expert Partnerships at FH including IHEP, which specializes in diseases of the liver and i-ONE, which specializes in oncology and hematology. Each Expert Partnership offers unparalleled access to the latest insights from the world’s leading key opinion leaders.

FIDE’s services range from detailed, unbiased conference analysis programs to consulting and training initiatives that bridge the gap between industry’s understanding of the field and real-world clinician and patient perspectives.

We sat down with members of the FIDE Steering Committee to explore the latest key insights and trends in 5 inflammatory skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa. They examined the complexities of the space and outlined the challenges that new and innovative treatments and technologies can help address, from meeting unmet needs to improving in the provision of high standards of clinical care.

CLICK HERE TO DOWNLOAD FULL ARTICLE

This content was provided by Avalere Health

Company Details

 Latest Content from  Avalere Health 

6 trends shaping the future of personalized medicine

Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators.

The Evolving Role of the Sales Rep

The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...

Measure your omnichannel maturity with our new tool

Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness.

Report: Omnichannel advice for the life science industry

In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...

6 trends shaping the future of personalized medicine

Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators.

Omnichannel strategies to revolutionize the healthcare professional experience

Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...

The digital-first launch: the key to connected stakeholder experiences?

During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...

Learning and development: the secret weapon for a successful life science launch

Dave Stuteville, Executive Vice President, Learning & Development, reveals the principles behind successfully training Sales Representatives and Medical Science Liaisons for a rapid biopharmaceutical product launch.

Data-driven policy and market access firm Avalere joins Fishawack Health

Fishawack Health bolsters its commercialization service offering with its largest addition to date, welcoming US-based policy, market access, and transformation leader Avalere.

Fishawack Health expands its value, evidence, and market access capabilities with the acquisition of HEOR consultancy Policy Analysis Inc. (PAI)

Fishawack Health announces its expanded global Value, Evidence, and Access (VEA) capability for biopharmaceutical and medical technology companies, with a suite of end-to-end services spanning product lifecycle, coupled with unsurpassed...